Aflibercept biosimilar (Mabwell)

阿柏西普生物类似药（迈威）

Report date: 2025/11/06 14:51:21

Base Information

Drug NameAflibercept biosimilar (Mabwell)
Drug Alias Name阿柏西普生物类似药Eylea Biosimiliar(Mabwell)9MW08139-MW08139MW-0813 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesMabwell (Shanghai) Bioscience Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu T-Mab Bio-Pharmaceuticals Co LtdShanghai Destiny Biotech Co LtdMabwell (Shanghai) Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG